- Home
- CNNE vs ELVN Comparison
CNNE vs ELVN Comparison
Compare CNNE & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNNE
- ELVN
- Stock Information
- Founded
- CNNE 2014
- ELVN 2016
- Country
- CNNE United States
- ELVN United States
- Employees
- CNNE N/A
- ELVN N/A
- Industry
- CNNE Restaurants
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- CNNE Consumer Discretionary
- ELVN Health Care
- Exchange
- CNNE Nasdaq
- ELVN Nasdaq
- Market Cap
- CNNE 1.1B
- ELVN 1.2B
- IPO Year
- CNNE N/A
- ELVN 2020
- Fundamental
- Price
- CNNE $18.85
- ELVN $20.90
- Analyst Decision
- CNNE Buy
- ELVN Strong Buy
- Analyst Count
- CNNE 3
- ELVN 5
- Target Price
- CNNE $23.33
- ELVN $41.20
- AVG Volume (30 Days)
- CNNE 570.1K
- ELVN 422.6K
- Earning Date
- CNNE 11-11-2025
- ELVN 11-12-2025
- Dividend Yield
- CNNE 3.21%
- ELVN N/A
- EPS Growth
- CNNE N/A
- ELVN N/A
- EPS
- CNNE N/A
- ELVN N/A
- Revenue
- CNNE $437,200,000.00
- ELVN N/A
- Revenue This Year
- CNNE N/A
- ELVN N/A
- Revenue Next Year
- CNNE N/A
- ELVN $20.05
- P/E Ratio
- CNNE N/A
- ELVN N/A
- Revenue Growth
- CNNE N/A
- ELVN N/A
- 52 Week Low
- CNNE $15.92
- ELVN $13.30
- 52 Week High
- CNNE $22.36
- ELVN $29.79
- Technical
- Relative Strength Index (RSI)
- CNNE 53.71
- ELVN 52.29
- Support Level
- CNNE $18.25
- ELVN $20.10
- Resistance Level
- CNNE $18.87
- ELVN $22.36
- Average True Range (ATR)
- CNNE 0.37
- ELVN 0.93
- MACD
- CNNE 0.05
- ELVN -0.05
- Stochastic Oscillator
- CNNE 83.33
- ELVN 37.85
About CNNE Cannae Holdings Inc.
Cannae Holdings Inc is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant Group, Dun & Bradstreet, Alight, BKFC, Corporate and Other. Majority of the company's revenue is generated from its Restaurant Group segment which represents the operations of O'Charley's and Ninety Nine Restaurants.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.